

CITATION REPORT

List of articles citing

Understanding and applying pharmacometric modelling and simulation in clinical practice and research

DOI: 10.1111/bcp.13119

British Journal of Clinical Pharmacology, 2017, 83, 247-254.

Source: <https://exaly.com/paper-pdf/67711725/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
67	Why standards are useful for predicting doses. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 685-687	3.8	19
66	Biomarkers in epilepsy-A modelling perspective. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 109S, S47-S52	5.1	2
65	What is the best size predictor for dose in the obese child?. <i>Paediatric Anaesthesia</i> , 2017 , 27, 1176-1184	1.8	36
64	Understanding and applying pharmacometric modelling and simulation in clinical practice and research. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 247-254	3.8	53
63	Application of pharmaceutical sciences to modern pharmacy practice. <i>Journal of Pharmacy Practice and Research</i> , 2017 , 47, 416-417	0.7	
62	Pharmacokinetics of Chlorin eCobalt Bis(Dicarbollide) Conjugate in Balb/c Mice with Engrafted Carcinoma. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	7
61	The clinical utility of pharmacometric models. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1413-1414	3.8	2
60	Drug error in paediatric anaesthesia: current status and where to go now. <i>Current Opinion in Anaesthesiology</i> , 2018 , 31, 333-341	2.9	4
59	Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants. <i>Frontiers in Pediatrics</i> , 2018 , 6, 325	3.4	15
58	Evaluation and translation of combination therapies in oncology - A quantitative approach. <i>European Journal of Pharmacology</i> , 2018 , 834, 327-336	5.3	3
57	Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 573-580	4.5	0
56	Spotlight Commentary: Model-informed precision dosing must demonstrate improved patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2238-2240	3.8	11
55	Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. <i>BioDrugs</i> , 2019 , 33, 453-468	7.9	7
54	Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2984-2993	5.1	4
53	Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1829-1840	3.8	4
52	The Risk of Treating Populations Instead of Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 256-258	4.5	2
51	Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 885-895	15.4	23

50	Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1312-1325	3.8	4
49	Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1326-1336	3.8	25
48	Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1099-1106	3.8	3
47	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019 , 103, 2012-2030	1.8	19
46	GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies - development and application in pediatric antibiotic studies. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 1091-1098	3.8	7
45	Covariate Analysis in Clinical Anaesthesia. 2019 , 40-62		
44	Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 557-567	6.1	9
43	Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 376-387	6.1	6
42	Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 123-135	6.2	1
41	Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	1
40	Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2020 , 28, 1217-1227	4.4	1
39	Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation. <i>Pediatric Transplantation</i> , 2020 , 24, e13616	1.8	1
38	Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020 , 11, 316	5.6	3
37	A framework for simplification of quantitative systems pharmacology models in clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2020 ,	3.8	6
36	Impact of gastrointestinal physiology on drug absorption in special populations--An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 147, 105280	5.1	63
35	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020 , 13, 400-409	4.9	5
34	Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 53-68	6.2	7
33	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021 , 61, 225-245	17.9	20

32	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1-16	6.2	2
31	Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. <i>MABs</i> , 2021 , 13, 1964935	6.6	1
30	The ADME Encyclopedia. 2021 , 1-7		
29	Improving the Safety of Pediatric Sedation: Human Error, Technology, and Clinical Microsystems. 2021 , 721-752		
28	Nonparametric goodness-of-fit testing for parametric covariate models in pharmacometric analyses. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 564-576	4.5	0
27	Population pharmacokinetics of oxcarbazepine: a systematic review. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 853-864	3.8	1
26	Step-by-step comparison of ordinary differential equation and agent-based approaches to pharmacokinetic-pharmacodynamic models. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021	4.5	1
25	Population pharmacokinetic-pharmacodynamic modeling of acetaminophen in preterm neonates with hemodynamically significant patent ductus arteriosus. <i>European Journal of Pharmaceutical Sciences</i> , 2021 , 167, 106023	5.1	0
24	Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice. <i>Arhiv Za Farmaciju</i> , 2021 , 71, 336-353	0.2	
23	Physiological and pathological processes of synaptic plasticity and memory in drug discovery: Do not forget the dose-response curve. <i>European Journal of Pharmacology</i> , 2017 , 817, 59-70	5.3	6
22	Pharmacokinetic and Pharmacodynamic Modeling. 2020 , 1-24		1
21	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. 2020 , 199-220		
20	The PHARMACOM-EPI framework for integrating pharmacometric modelling into pharmacoepidemiological research using real-world data: application to assess death associated with valproate. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	1
19	Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update.. <i>Antibiotics</i> , 2022 , 11,	4.9	2
18	Pharmacometrics Approaches and its Applications in Diabetes: An Overview.. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021 , 13, 335-340	1.1	
17	The Relationship between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.. <i>Journal of Clinical Pharmacology</i> , 2022 ,	2.9	0
16	Twice neglected? Neglected diseases in neglected populations. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
15	Table_1.docx. 2020 ,		

14 Table_2.docx. **2020**,

13 Treatment response prediction: Is model selection unreliable?.

12 Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice. *Journal of Clinical Medicine*, **2022**, 11, 3009 5.1 2

11 Pharmacometrics in Precision Dosing. **2022**, 927-933

10 Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines. *Frontiers in Pharmacology*, 13, 5.6

9 Pharmacokinetic and Pharmacodynamic Modeling. **2022**, 1937-1960 ○

8 Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors. ○

7 General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimisation of study protocols for small molecules and monoclonal antibodies in children. ○

6 Challenges and Possible Solutions to Direct-Acting Oral Anticoagulants (DOACs) Dosing in Patients with Extreme Bodyweight and Renal Impairment. ○

5 Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases. **2022**, 62, 1

4 Parametric population pharmacokinetics of isoniazid: a systematic review. 1-23 ○

3 Nonmammalian models in toxicology screening. **2023**, ○

2 In Silico Pharmacology for Evidence-Based and Precision Medicine. **2023**, 15, 1014 ○

1 *Escherichia coli* extended spectrum beta-lactamase meningitis in 3-months infant with subdural abscess and communicating hydrocephalus: A case report. **2023**, 106, 108128 ○